Skip to main content
SpringerLink
Log in

Pharmacometrics of Viral Infections

  • Chapter
  • First Online:
Applied Pharmacometrics

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 14))

  • 2625 Accesses

Abstract

Antiviral drugs play a crucial role in the treatment of human infections caused by viral pathogens. In order for antiviral therapy to be efficacious, the optimal dose and dosing interval for each compound must be identified. Optimal dosage regimens are defined as regimens that maximize inhibition of viral replication, prevent the emergence of resistance, and demonstrate minimal toxicity. Pharmacometrics can be applied to guide in the intelligent design of optimal dosage regimens for antiviral compounds. But in order for this approach to be successful, a deep understanding of the pharmacokinetic (PK) and pharmacodynamic (PD) properties of each compound must be delineated. In this chapter, we describe the use of in vitro PD model systems to elucidate the PD and PK/PD interactions for several antiviral agents active against human immunodeficiency virus (HIV), hepatitis C virus (HCV), or influenza A virus. We also discuss how this information derived from “benchtop” experiments can be directly applied to the “bedside” or clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Apostolova N, Blas-Garcia A, Esplugues J V (2011a) Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-gamma inhibition. Trends Pharmacol Sci 32:715–725

    Google Scholar 

  • Apostolova N, Blas-Garcia A, Esplugues JV (2011b) Mitochondrial toxicity in HAART: an overview of in vitro evidence. Curr Pharm Des 17:2130–2144

    Google Scholar 

  • Besselaar TG, Naidoo D, Buys A, Gregory V, McAnerney J, Manamela JM, Blumberg L, Schoub BD (2008) Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 14:1809–1810

    Article  PubMed Central  PubMed  Google Scholar 

  • Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL (1994) Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother 38:1386–1391

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–894

    Article  CAS  PubMed  Google Scholar 

  • Brown AN, McSharry JJ, Weng Q, Driebe EM, Engelthaler DM, Sheff K, Keim PS, Nguyen J, Drusano GL (2010) In vitro system for modeling influenza A virus resistance under drug pressure. Antimicrob Agents Chemother 54:3442–3450

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL (2011a) Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob Agents Chemother 55:1747–1753

    Google Scholar 

  • Brown AN, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL (2011b) Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 55:1740–1746

    Google Scholar 

  • Brown AN, McSharry JJ, Adams JR, Kulawy R, Barnard RJ, Newhard W, Corbin A, Hazuda DJ, Louie A, Drusano GL (2012) Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system. Antimicrob Agents Chemother 56:1170–1181

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • CDC (2006) High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents—United States, 2005–2006 influenza season. MMWR Morb Mortal Wkly Rep 55:44–46

    Google Scholar 

  • CDC (2009a) Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009. MMWR Morb Mortal Wkly Rep 58:969–972

    Google Scholar 

  • CDC (2009b) Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients—Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 58:893–896

    Google Scholar 

  • CDC (2009c) Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 58:433–435

    Google Scholar 

  • Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258–1261

    Article  CAS  PubMed  Google Scholar 

  • Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196:249–257

    Article  CAS  PubMed  Google Scholar 

  • Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, St George K, Epperson S, Brammer L, Klimov AI, Bresee JS, Fry AM (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034–1041

    Article  CAS  PubMed  Google Scholar 

  • Drake JW (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90:4171–4175

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Drusano GL, D’Argenio DZ, Symonds W, Bilello PA, McDowell J, Sadler B, Bye A, Bilello JA (1998) Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 42:2153–2159

    CAS  PubMed Central  PubMed  Google Scholar 

  • Drusano GL, D’Argenio DZ, Preston SL, Barone C, Symonds W, LaFon S, Rogers M, Prince W, Bye A, Bilello JA (2000) Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 44:1655–1659

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Drusano GL, Bilello JA, Preston SL, O’Mara E, Kaul S, Schnittman S, Echols R (2001) Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis 183:1126–1129

    Article  CAS  PubMed  Google Scholar 

  • Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A, Bilello JA (2002a) Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob Agents Chemother 46:464–470

    Google Scholar 

  • Drusano GL, Moore KH, Kleim JP, Prince W, Bye A (2002b) Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 46:913–916

    Google Scholar 

  • Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36:S237–S244

    Article  PubMed  Google Scholar 

  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982

    Article  CAS  PubMed  Google Scholar 

  • Ghedin E, Laplante J, DePasse J, Wentworth DE, Santos RP, Lepow ML, Porter J, Stellrecht K, Lin X, Operario D, Griesemer S, Fitch A, Halpin RA, Stockwell TB, Spiro DJ, Holmes EC, St GK (2011) Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. J Infect Dis 203:168–174

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ghedin E, Holmes EC, DePasse JV, Pinilla LT, Fitch A, Hamelin ME, Papenburg J, Boivin G (2012) Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. J Infect Dis 206:1504–1511

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331–385

    CAS  PubMed  Google Scholar 

  • Haas DW, Arathoon E, Thompson MA, de Jesus PR, Gallant JE, Uip DE, Currier J, Noriega LM, Lewi DS, Uribe P, Benetucci L, Cahn P, Paar D, White AC, Jr, Collier AC, Ramirez-Ronda CH, Harvey C, Chung MO, Mehrotra D, Chodakewitz J, Nguyen BY (2000) Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS 14:1973–1978

    Article  CAS  PubMed  Google Scholar 

  • Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes, O (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–2008. Emerg Infect Dis 15:155–162

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Holland JJ, De La Torre JC, Steinhauer DA (1992) RNA virus populations as quasispecies. Curr Top Microbiol Immunol 176:1–20

    CAS  PubMed  Google Scholar 

  • Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KA (2001) Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 276:40847–40857

    Article  CAS  PubMed  Google Scholar 

  • de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667–2672

    Article  CAS  PubMed  Google Scholar 

  • Krumbholz A, Schmidtke M, Bergmann S, Motzke S, Bauer K, Stech J, Durrwald R, Wutzler P, Zell R (2009) High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol 90:900–908

    Article  CAS  PubMed  Google Scholar 

  • Lee H, Hanes J, Johnson KA (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711–14719

    Article  CAS  PubMed  Google Scholar 

  • Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71–75

    Article  CAS  PubMed  Google Scholar 

  • Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A (2000) The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 40:836–843

    Article  CAS  PubMed  Google Scholar 

  • Matsuzaki Y, Mizuta K, Aoki Y, Suto A, Abiko C, Sanjoh K, Sugawara K, Takashita E, Itagaki T, Katsushima Y, Ujike M, Obuchi M, Odagiri T, Tashiro M (2010) A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J 7:53

    Article  PubMed Central  PubMed  Google Scholar 

  • McSharry JJ, Deziel MR, Zager K, Weng Q, Drusano GL (2009a) Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 53:129–135

    Google Scholar 

  • McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL (2009b). Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 53:2375–2381

    Google Scholar 

  • Moscona A (2005) Oseltamivir resistance—disabling our influenza defenses. N Engl J Med 353:2633–2636

    Article  CAS  PubMed  Google Scholar 

  • Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, Craig C, Scott TR (2005) Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the ziagen once daily in antiretroviral combination study. J Acquir Immune Defic Syndr 38:417–425

    Article  CAS  PubMed  Google Scholar 

  • Mulder JW, Cooper DA, Mathiesen L, Sandstrom E, Clumeck N, Gatell JM, French M, Donovan B, Gray F, Yeo JM (1994) Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). AIDS 8:313–321

    Article  CAS  PubMed  Google Scholar 

  • Piliero P, Shachoy-Clark AD, Para M, Preston S, Lou Y, Drusano GL, Stein DS, Yuen GJ (2003) A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK Protocol CNA10905), abstr. A-1797. Abstr 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago

    Google Scholar 

  • Preston SL, Piliero PJ, Bilello JA, Stein DS, Symonds WT, Drusano GL (2003) In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours. Antimicrob Agents Chemother 47:3393–3399

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ruane PJ, Richmond GJ, DeJesus E, Hill-Zabala CE, Danehower SC, Liao Q, Johnson J, Shaefer MS (2004) Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naive patients infected with human immunodeficiency virus. Pharmacotherapy 24:307–312

    Article  CAS  PubMed  Google Scholar 

  • Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767–1777

    Article  CAS  PubMed  Google Scholar 

  • Slusher JT, Kuwahara SK, Hamzeh FM, Lewis LD, Kornhauser DM, Lietman PS (1992) Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 36:2473–2477

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research and Academic Center, Institute for Therapeutic Innovation, University of Florida, Orlando, FL, USA

    George L. Drusano MD & Ashley N. Brown PhD

Authors
  1. George L. Drusano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashley N. Brown PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashley N. Brown PhD .

Editor information

Editors and Affiliations

  1. University of Florida, Department of Pharmaceutics, Center for Pharmacometrics & Systems Pharmacology, Orlando, Florida, USA

    Stephan Schmidt

  2. University of Florida, College of Pharmacy, Department of Pharmaceutics, Gainesville, Florida, USA

    Hartmut Derendorf

Rights and permissions

Reprints and permissions

Copyright information

© 2014 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Drusano, G., Brown, A. (2014). Pharmacometrics of Viral Infections. In: Schmidt, S., Derendorf, H. (eds) Applied Pharmacometrics. AAPS Advances in the Pharmaceutical Sciences Series, vol 14. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1304-6_9

Download citation

Publish with us

Policies and ethics

Search

Navigation